Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{f8d85ae7855644d5905e530969c6aae2,
title = "Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study",
abstract = "OBJECTIVE: The sentinel node (SN) procedure is adopted in selected patients with early-stage vulva cancer (VC) in Denmark. Due to the low incidence of VC, large population-based studies on the safety of SN outside multicenter clinical trials are lacking. The current study evaluated the risk of recurrence and survival in SN- negative VC patients.METHODS: Nationwide data was collected and registered prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor <4 cm and no clinically suspicious groin nodes or distant metastases, who underwent SN-procedure, were included.RESULTS: The SN-procedure was performed in 286 patients, of these 190 (66.4{\%}) patients were SN-negative. Twenty-three of the 190 SN-negative patients (12.1{\%}) had one or more recurrences during a median follow-up of 30 months (range 1-83). Four patients (2.1{\%}) had an isolated groin recurrence identified from 5 to 17 months after primary surgery. Fourteen patients (7.4{\%}) experienced a local recurrence in vulva, 1 patient (0.5{\%}) had a recurrence in the vulva and the groin and 4 patients (2.1{\%}) had distant recurrences. The 3-year overall (OS) and disease-specific survival (DSS) for SN-negative patients was 84{\%} and 93{\%}, respectively. The 3-year OS for patients with recurrent disease was 58{\%}.CONCLUSIONS: This is the largest prospective nationwide study on SN-procedure in vulva cancer. The study confirms the safety of the SN-procedure in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.",
author = "Froeding, {Ligita Paskeviciute} and Claus H{\o}gdall and Elisabeth Kristensen and Vibeke Zobbe and Isa Niemann and Gitte {\O}rtoft and Ingrid Thranov and Ole Mathiesen and Jann Mortensen and Schnack, {Tine Henrichsen}",
note = "Copyright {\circledC} 2019 Elsevier Inc. All rights reserved.",
year = "2020",
doi = "10.1016/j.ygyno.2019.10.024",
language = "English",
volume = "156",
pages = "124--130",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press",
number = "1",

}

RIS

TY - JOUR

T1 - Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study

AU - Froeding, Ligita Paskeviciute

AU - Høgdall, Claus

AU - Kristensen, Elisabeth

AU - Zobbe, Vibeke

AU - Niemann, Isa

AU - Ørtoft, Gitte

AU - Thranov, Ingrid

AU - Mathiesen, Ole

AU - Mortensen, Jann

AU - Schnack, Tine Henrichsen

N1 - Copyright © 2019 Elsevier Inc. All rights reserved.

PY - 2020

Y1 - 2020

N2 - OBJECTIVE: The sentinel node (SN) procedure is adopted in selected patients with early-stage vulva cancer (VC) in Denmark. Due to the low incidence of VC, large population-based studies on the safety of SN outside multicenter clinical trials are lacking. The current study evaluated the risk of recurrence and survival in SN- negative VC patients.METHODS: Nationwide data was collected and registered prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor <4 cm and no clinically suspicious groin nodes or distant metastases, who underwent SN-procedure, were included.RESULTS: The SN-procedure was performed in 286 patients, of these 190 (66.4%) patients were SN-negative. Twenty-three of the 190 SN-negative patients (12.1%) had one or more recurrences during a median follow-up of 30 months (range 1-83). Four patients (2.1%) had an isolated groin recurrence identified from 5 to 17 months after primary surgery. Fourteen patients (7.4%) experienced a local recurrence in vulva, 1 patient (0.5%) had a recurrence in the vulva and the groin and 4 patients (2.1%) had distant recurrences. The 3-year overall (OS) and disease-specific survival (DSS) for SN-negative patients was 84% and 93%, respectively. The 3-year OS for patients with recurrent disease was 58%.CONCLUSIONS: This is the largest prospective nationwide study on SN-procedure in vulva cancer. The study confirms the safety of the SN-procedure in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.

AB - OBJECTIVE: The sentinel node (SN) procedure is adopted in selected patients with early-stage vulva cancer (VC) in Denmark. Due to the low incidence of VC, large population-based studies on the safety of SN outside multicenter clinical trials are lacking. The current study evaluated the risk of recurrence and survival in SN- negative VC patients.METHODS: Nationwide data was collected and registered prospectively in the Danish Gynecologic Cancer Database from January 2011 to July 2017. Patients with clinically stage IB-II unifocal vulva squamous cell carcinoma, tumor <4 cm and no clinically suspicious groin nodes or distant metastases, who underwent SN-procedure, were included.RESULTS: The SN-procedure was performed in 286 patients, of these 190 (66.4%) patients were SN-negative. Twenty-three of the 190 SN-negative patients (12.1%) had one or more recurrences during a median follow-up of 30 months (range 1-83). Four patients (2.1%) had an isolated groin recurrence identified from 5 to 17 months after primary surgery. Fourteen patients (7.4%) experienced a local recurrence in vulva, 1 patient (0.5%) had a recurrence in the vulva and the groin and 4 patients (2.1%) had distant recurrences. The 3-year overall (OS) and disease-specific survival (DSS) for SN-negative patients was 84% and 93%, respectively. The 3-year OS for patients with recurrent disease was 58%.CONCLUSIONS: This is the largest prospective nationwide study on SN-procedure in vulva cancer. The study confirms the safety of the SN-procedure in selected early-stage VC patients with a low isolated groin recurrence rate and a good DSS.

U2 - 10.1016/j.ygyno.2019.10.024

DO - 10.1016/j.ygyno.2019.10.024

M3 - Journal article

VL - 156

SP - 124

EP - 130

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 1

ER -

ID: 58995385